T-Vec talimogene laherparepvec: Additional Phase III data

The open-label, international Phase III OPTiM trial in 436 patients with stage IIIb-IV melanoma showed that Imlygic led to a DRR, the primary endpoint defined as the rate of CR or PR lasting continuou...